miRagen Therapeutics and Santaris Pharma expand global alliance for microRNA drug discovery

By: Steve Thursday January 10, 2013 0 comments Tags: Boulder, Henrik Oerum, microRNA, miRagen Therapeutics, Santaris Pharma, William Marshall

miRagen logo
BOULDER - miRagen Therapeutics and Denmark-based Santaris Pharma A/S announced they are expanding an existing partnership to discover and produce drugs to treat more diseases caused by microRNAs.

Under the expanded agreement, miRagen obtains a broad, non-exclusive license in the miRNA therapeutics field for world-wide exclusive rights to research, develop and commercialize LNA (locked nucleic acid) drugs against up to six additional microRNA targets that have been shown to be important in human disease areas of high unmet need.

It brings the total of microRNA targets under the agreement to 10, Santaris said. Santaris will receive a combination of cash and equity for the licenses as well as clinical milestones and royalties on products emerging from the alliance.

Financial terms of the agreement were not disclosed.

"Our collaboration with miRagen is an important part of our corporate strategy in the micoRNA therapeutics field, so we are very pleased with our collective decision to expand the relationship," said Henrik Oerum, Santaris' vice president and CSO.

"Our partnership with Santaris has been very productive, and we are excited to expand the relationship to additional microRNA targets in our portfolio," said William Marshall, miRagen president and CEO.

"Our goal is to identify important disease-causing microRNAs and to deploy the world's best technologies to create therapeutic development candidates against diseases with high unmet medical need. We hope these new programs will translate into novel drugs that will help patients suffering from serious diseases live longer and better lives."

For more information, visit www.santaris.com or www.miragenrx.com.

About the Author: Steve